LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

Launched by ZHEJIANG UNIVERSITY · Jun 19, 2023

Keywords

ClinConnect Summary

The LISH Trial is a study aimed at comparing two surgical methods for treating specific types of colon cancer, particularly hepatic flexure colon cancer and proximal transverse colon cancer. Researchers want to see if a newer technique called Laparoscopic Ileocecal-Sparing Right Hemicolectomy (LISH) is as effective as the traditional approach known as laparoscopic right hemicolectomy (TRH) in helping patients live longer and healthier after surgery. The trial is currently looking for participants aged between 18 and 75 years who have been diagnosed with colon adenocarcinoma and have certain imaging results showing the cancer is in the targeted area.

If you or someone you know is considering joining this trial, participants can expect to undergo one of the two surgical procedures and will be closely monitored by the medical team throughout the process. To be eligible, participants need to have a confirmed diagnosis of colon cancer, be in good overall health, and be able to understand and provide consent for the study. It’s important to note that certain medical conditions, previous cancer treatments, or surgeries may disqualify potential participants. This trial is an opportunity to contribute to important research that could improve treatment options for colon cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age between 18-75 years old
• • 2. ASA classification ≤III
• • 3. Colon adenocarcinoma confirmed by endoscopy and pathological biopsy
• • 4. Enhanced abdominal CT indicating the primary lesion is located in the hepatic flexure of the colon or proximal transverse colon (proximal 1/3 of the transverse colon)
• • 5. Preoperative clinical staging: TanyNanyM0
• • 6. Patients able to understand the study protocol, willing to participate in the research, and providing written informed consent
• Exclusion Criteria:
• • 1. Preoperative examination indicates synchronous multiple primary colorectal cancers or other diseases requiring bowel segment resection
• • 2. Preoperative imaging or intraoperative exploration reveals: 1) tumor involving surrounding organs requiring combined organ resection; 2) presence of distant metastasis; 3) inability to perform R0 resection; 4) fused and fixed lymph nodes at the root of the ileocolic vessels
• • 3. Additional radical surgery following Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) procedures
• • 4. History of any other malignant tumor within the last 5 years or familial adenomatous polyposis, except for cured in situ cervical cancer, basal cell carcinoma, papillary thyroid carcinoma, or skin squamous cell carcinoma
• • 5. Presence of bowel obstruction, bowel perforation, or intestinal bleeding requiring emergency surgery
• • 6. Patients unsuitable for or unable to tolerate laparoscopic surgery
• • 7. Pregnant or lactating women
• • 8. Patients with a history of psychiatric disorders
• • 9. Patients who have received neoadjuvant therapy prior to surgery
• • 10. Patients deemed unsuitable for the study by MDT discussion
• • 11. Patients unable to understand the study's conditions and objectives, and refusing to sign informed consent.